Lung adenocarcinomas harboring oncogenic driver mutations at the level of EGFR and ROS1 and ALK rearrangements have a lower mutational load, often occur in never smokers and are sensitive to targeting with specific inhibitors and this offered new therapeutic perspectives for these patients. The gene discussed is ALK; the disease is lung adenocarcinoma.